Touria ELDHIMNI

Mrs. Touria ELDHIMNI


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Hemato
Verified
Journal Article
Open access
PDF file
HHHanane Ait hammou
Hanane Ait hammou
ENELHIDAR Najoua
ELHIDAR Najoua
Mourad OUHAMMOUMourad OUHAMMOU
Mourad OUHAMMOU
WSWafa Sansar
Wafa Sansar
SFSamira Fazzani
Samira Fazzani
MEMohamed Sif Essalam
Mohamed Sif Essalam
Background/Objectives: Erythrocyte alloimmunization is a critical complication impacting the efficacy of transfusion therapy in patients with thalassemia. This study seeks to evaluate the prevalence, characterization, and determinants of erythrocyte alloimmunization in multi-transfused thalassemia patients in south of Morocco. Methods: A retrospective study was conducted at the Moroccan Blood and Blood Derivatives Agency in Marrakech (Morocco) over 2 years, from June 2022 to June 2024, including 89 patients with beta-thalassemia receiving regular transfusions. The clinical, demographic, and transfusion characteristics of patients who developed alloimmunization were compared with those of non-alloimmunized patients. Results: Analysis of 89 β-thalassemia patients in the Marrakech region, mostly young and suffering from major form (67%), shows a significant male predominance (p = 0.004) and a high frequency of blood group O+ (49.4%). Alloimmunization mainly affects major forms and males and is associated with frequent annual transfusions (over 12 per year), usually resulting in the use of 24 to 60 packed red blood cell units annually. Alloimmunized patients mostly present anti-K and anti-E antibodies, indicating the involvement of the Kell and Rh systems. The direct Coombs test was more often positive in these patients (21.4% vs. 7.9%, p < 0.01). Conclusions: The high prevalence of alloimmunization in thalassemia patients in the Marrakech region highlights the need for a rigorous and personalized transfusion strategy, including molecular genotyping and alternative therapies.

5 October 2026 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
AMAit Melloul Abdelaziz Ait Melloul
Ait Melloul Abdelaziz Ait Melloul
Morad KaddouriMorad Kaddouri
Morad Kaddouri
Mourad OUHAMMOUMourad OUHAMMOU
Mourad OUHAMMOU
MBMustapha Barakate
Mustapha Barakate
TETouria ELDHIMNI
Touria ELDHIMNI
LHLahcen Hassani
Lahcen Hassani
Background: TTIs remain a major threat to transfusion safety. This study assessed the association between ABO/Rh blood groups and HBV, HIV, HCV, and syphilis among 4.038 apparently healthy blood donors. Methods: A retrospective cross-sectional study was conducted at the Moroccan Blood Agency and its Derivatives in Marrakech. Serological markers were detected using the Architect i2000SR chemiluminescent microparticle immunoassay (Abbott®, USA). ABO/Rh phenotyping was performed by forward and reverse grouping. Associations were assessed using Pearson’s chi-square test and logistic regression, with adjusted odds ratios. Results: Overall, 885 of 4.038 donors (21.92%) tested positive for at least one TTI marker, for at least one TTI. The highest prevalence of HBV was observed among blood group B donors (9.55%), whereas syphilis was most frequent in group AB (10.76%). HCV prevalence was highest in groups B (3.18%) and AB (3.07%), while HIV prevalence was highest in groups AB (4.61%) and O (4.50%). Regarding the Rh system, HBV, HCV, and HIV prevalence was comparable between Rh-positive and Rh-negative donors (8.94% vs. 8.06%, 2.56% vs. 2.41%, and 4.39% vs. 4.83%, respectively), whereas syphilis was more common among Rh-positive donors (6.71% vs. 4.56%). Compared with blood group O, the odds of HBV reactivity were similar among groups A (p = 0.317), B (p = 0.771), and AB (p = 0.837). Similarly, no significant associations were observed for HCV or HIV across the ABO groups (p > 0.05). For syphilis, donors with blood group AB had higher odds of reactive screening results than those with group O (COR = 1.74, 95% CI: 1.07–2.84; p = 0.025); but overall ABO association was not significant (p = 0.088). Multiple reactive serological profiles were mainly observed among O+ donors (9/16), including two triple-reactive profiles involving HBV, syphilis, and HIV. Conclusions: These findings indicated that ABO and Rh blood group systems were not significantly associated with any reactive serological markers.